Moderna Files For FDA Authorization Of Its Updated COVID-19 Vaccine
Portfolio Pulse from Benzinga Newsdesk
Moderna has filed for FDA authorization of its updated COVID-19 vaccine, XBB.1.5, which targets XBB variants. Preliminary clinical data shows a robust immune response, and the company is prepared to deliver the vaccine in time for the fall vaccination season.
June 22, 2023 | 8:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Moderna filed for FDA authorization of its updated COVID-19 vaccine, XBB.1.5, targeting XBB variants. The vaccine demonstrated a robust immune response and is expected to be available for the fall vaccination season.
Moderna's updated COVID-19 vaccine targeting XBB variants has shown promising preliminary results, and if authorized, it will be available for the fall vaccination season. This development is likely to have a positive impact on Moderna's stock price as it demonstrates the company's ability to adapt to new virus strains and maintain its position in the vaccine market.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100